{"id": "article-37376_0", "title": "PCSK9 Inhibitors -- Continuing Education Activity", "content": "Proprotein convertase subtilisin/kexin type 9 (PCSK9) has emerged as an important regulator of cholesterol metabolism. In the United States, 2 fully humanized monoclonal antibodies\u2014alirocumab and evolocumab\u2014 have been approved by the US Food and Drug Administration (FDA) to inhibit or reduce PCSK9 activity. Recently, both the European Union and FDA have approved inclisiran, a small interfering mRNA, that inhibits intracellular PCSK9 synthesis. Increased PCSK9 activity correlates with heightened LDL-C levels, while specific gain-of-function mutations lead to autosomal dominant familial hypercholesterolemia characterized by extremely high total and low-density lipoprotein (LDL) cholesterol levels, premature atherosclerotic vascular disease, and the formation of tendon xanthomas. In most cases, this is due to a genetic mutation of the LDL receptor caused by mutations of the apoprotein B100 or PCSK9 genes. Conversely, individuals with reduced PCSK9 activity, whether\u00a0due to\u00a0genetic polymorphism or the administration of PCSK9 monoclonal antibodies, exhibit lower cholesterol levels and a reduced risk of cardiovascular disease. This activity outlines\u00a0the indications, mechanism of action, administration methods, significant adverse effects, contraindications, monitoring, and toxicity of PCSK9 inhibitors. This activity also helps the interprofessional healthcare team tailor patient therapy for optimal outcomes in serum lipid management and improve cardiovascular outcomes.", "contents": "PCSK9 Inhibitors -- Continuing Education Activity. Proprotein convertase subtilisin/kexin type 9 (PCSK9) has emerged as an important regulator of cholesterol metabolism. In the United States, 2 fully humanized monoclonal antibodies\u2014alirocumab and evolocumab\u2014 have been approved by the US Food and Drug Administration (FDA) to inhibit or reduce PCSK9 activity. Recently, both the European Union and FDA have approved inclisiran, a small interfering mRNA, that inhibits intracellular PCSK9 synthesis. Increased PCSK9 activity correlates with heightened LDL-C levels, while specific gain-of-function mutations lead to autosomal dominant familial hypercholesterolemia characterized by extremely high total and low-density lipoprotein (LDL) cholesterol levels, premature atherosclerotic vascular disease, and the formation of tendon xanthomas. In most cases, this is due to a genetic mutation of the LDL receptor caused by mutations of the apoprotein B100 or PCSK9 genes. Conversely, individuals with reduced PCSK9 activity, whether\u00a0due to\u00a0genetic polymorphism or the administration of PCSK9 monoclonal antibodies, exhibit lower cholesterol levels and a reduced risk of cardiovascular disease. This activity outlines\u00a0the indications, mechanism of action, administration methods, significant adverse effects, contraindications, monitoring, and toxicity of PCSK9 inhibitors. This activity also helps the interprofessional healthcare team tailor patient therapy for optimal outcomes in serum lipid management and improve cardiovascular outcomes."}
{"id": "article-37376_1", "title": "PCSK9 Inhibitors -- Continuing Education Activity", "content": "Objectives: Identify patients with familial\u00a0hypercholesterolemia who may benefit from PCSK9 inhibitor therapy based on their lipid profile and cardiovascular risk factors. Implement evidence-based practices for initiating and titrating PCSK9 inhibitors in eligible patients to achieve optimal low-density lipoprotein cholesterol reduction and cardiovascular risk management. Select appropriate strategies for managing adverse effects and addressing barriers to adherence in patients receiving PCSK9 inhibitors. Collaborate with specialists, clinical pharmacists, and other members of the interprofessional team to optimize patient care and ensure comprehensive management of hypercholesterolemia. Access free multiple choice questions on this topic.", "contents": "PCSK9 Inhibitors -- Continuing Education Activity. Objectives: Identify patients with familial\u00a0hypercholesterolemia who may benefit from PCSK9 inhibitor therapy based on their lipid profile and cardiovascular risk factors. Implement evidence-based practices for initiating and titrating PCSK9 inhibitors in eligible patients to achieve optimal low-density lipoprotein cholesterol reduction and cardiovascular risk management. Select appropriate strategies for managing adverse effects and addressing barriers to adherence in patients receiving PCSK9 inhibitors. Collaborate with specialists, clinical pharmacists, and other members of the interprofessional team to optimize patient care and ensure comprehensive management of hypercholesterolemia. Access free multiple choice questions on this topic."}
{"id": "article-37376_2", "title": "PCSK9 Inhibitors -- Indications", "content": "Proprotein convertase subtilisin/kexin type 9 (PCSK9) has emerged as an important regulator of cholesterol metabolism.\u00a0In the United States, 2 fully humanized monoclonal antibodies\u2014alirocumab and evolocumab\u2014 have been approved by the US Food and Drug Administration (FDA) to inhibit or reduce PCSK9 activity. [1] [2] Recently, both the European Union and FDA have approved inclisiran, a small interfering mRNA, to inhibit intracellular PCSK9 synthesis. [3] [4] [5]", "contents": "PCSK9 Inhibitors -- Indications. Proprotein convertase subtilisin/kexin type 9 (PCSK9) has emerged as an important regulator of cholesterol metabolism.\u00a0In the United States, 2 fully humanized monoclonal antibodies\u2014alirocumab and evolocumab\u2014 have been approved by the US Food and Drug Administration (FDA) to inhibit or reduce PCSK9 activity. [1] [2] Recently, both the European Union and FDA have approved inclisiran, a small interfering mRNA, to inhibit intracellular PCSK9 synthesis. [3] [4] [5]"}
{"id": "article-37376_3", "title": "PCSK9 Inhibitors -- Indications -- FDA-Approved Indications", "content": "The FDA has approved alirocumab\u00a0for adults with an established or high risk of cardiovascular disease and adults with familial hypercholesterolemia. To reduce the risk of myocardial infarction (MI), stroke, and unstable angina requiring hospitalization in adults with established cardiovascular disease. As an adjunct to diet, alone or in combination with other low-density lipoprotein (LDL) cholesterol (LDL-C)\u2013lowering therapies, for treating adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia, to reduce LDL-C. As an adjunct to diet and other LDL-C\u2013lowering therapies in adults with homozygous familial hypercholesterolemia to reduce LDL-C.", "contents": "PCSK9 Inhibitors -- Indications -- FDA-Approved Indications. The FDA has approved alirocumab\u00a0for adults with an established or high risk of cardiovascular disease and adults with familial hypercholesterolemia. To reduce the risk of myocardial infarction (MI), stroke, and unstable angina requiring hospitalization in adults with established cardiovascular disease. As an adjunct to diet, alone or in combination with other low-density lipoprotein (LDL) cholesterol (LDL-C)\u2013lowering therapies, for treating adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia, to reduce LDL-C. As an adjunct to diet and other LDL-C\u2013lowering therapies in adults with homozygous familial hypercholesterolemia to reduce LDL-C."}
{"id": "article-37376_4", "title": "PCSK9 Inhibitors -- Indications -- FDA-Approved Indications", "content": "The FDA has approved evolocumab\u00a0for use in adults with an established or high risk of cardiovascular disease risk, as well as in both adults and pediatric patients aged 10 or older with familial hypercholesterolemia. To reduce the risk of MI, stroke, and coronary revascularization in adults with established cardiovascular disease. As an adjunct to diet, alone or combined with other LDL-C\u2013lowering therapies for treating adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia to reduce LDL-C. As an adjunct to diet and other LDL-C\u2013lowering therapies in pediatric patients aged 10 and older with heterozygous familial hypercholesterolemia, to reduce LDL-C. As an adjunct to other LDL-C-lowering\u2013therapies in adults and pediatric patients aged 10 and older with homozygous familial hypercholesterolemia, to reduce LDL-C.", "contents": "PCSK9 Inhibitors -- Indications -- FDA-Approved Indications. The FDA has approved evolocumab\u00a0for use in adults with an established or high risk of cardiovascular disease risk, as well as in both adults and pediatric patients aged 10 or older with familial hypercholesterolemia. To reduce the risk of MI, stroke, and coronary revascularization in adults with established cardiovascular disease. As an adjunct to diet, alone or combined with other LDL-C\u2013lowering therapies for treating adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia to reduce LDL-C. As an adjunct to diet and other LDL-C\u2013lowering therapies in pediatric patients aged 10 and older with heterozygous familial hypercholesterolemia, to reduce LDL-C. As an adjunct to other LDL-C-lowering\u2013therapies in adults and pediatric patients aged 10 and older with homozygous familial hypercholesterolemia, to reduce LDL-C."}
{"id": "article-37376_5", "title": "PCSK9 Inhibitors -- Indications -- FDA-Approved Indications", "content": "As an adjunct to diet and maximally tolerated statin therapy\u00a0to treat adults with heterozygous familial hypercholesterolemia who require additional lowering of LDL-C. As an adjunct to diet and maximally tolerated statin therapy\u00a0to treat adults with clinical atherosclerotic cardiovascular disease who require additional lowering of LDL-C.", "contents": "PCSK9 Inhibitors -- Indications -- FDA-Approved Indications. As an adjunct to diet and maximally tolerated statin therapy\u00a0to treat adults with heterozygous familial hypercholesterolemia who require additional lowering of LDL-C. As an adjunct to diet and maximally tolerated statin therapy\u00a0to treat adults with clinical atherosclerotic cardiovascular disease who require additional lowering of LDL-C."}
{"id": "article-37376_6", "title": "PCSK9 Inhibitors -- Mechanism of Action", "content": "PCSK9 has emerged as an important regulator of cholesterol metabolism. [2] Increased PCSK9 activity correlates with heightened LDL-C levels, while specific gain-of-function mutations lead to autosomal dominant familial hypercholesterolemia characterized by extremely high total and LDL-C levels, premature atherosclerotic vascular disease, and the formation of tendon xanthomas. [6] [7] Conversely, individuals with reduced PCSK9 activity, whether\u00a0due to\u00a0genetic polymorphism or the administration of PCSK9 monoclonal antibodies, exhibit lower cholesterol levels and a reduced risk of cardiovascular disease. [8]", "contents": "PCSK9 Inhibitors -- Mechanism of Action. PCSK9 has emerged as an important regulator of cholesterol metabolism. [2] Increased PCSK9 activity correlates with heightened LDL-C levels, while specific gain-of-function mutations lead to autosomal dominant familial hypercholesterolemia characterized by extremely high total and LDL-C levels, premature atherosclerotic vascular disease, and the formation of tendon xanthomas. [6] [7] Conversely, individuals with reduced PCSK9 activity, whether\u00a0due to\u00a0genetic polymorphism or the administration of PCSK9 monoclonal antibodies, exhibit lower cholesterol levels and a reduced risk of cardiovascular disease. [8]"}
{"id": "article-37376_7", "title": "PCSK9 Inhibitors -- Mechanism of Action -- Normal Cholesterol Metabolism", "content": "LDL-C is normally cleared from the circulation as apoprotein B100 on the surface of LDL and binds to LDL receptors on hepatic and extrahepatic tissues. LDL bound to\u00a0these receptors undergoes a process of endocytosis. The endocytic vesicle fuses with lysosomes, increasing the intracellular concentration of free cholesterol. As the intracellular concentration of cholesterol increases,\u00a03 events occur, as mentioned below. [9] Decreased activity of 3-hydroxy-3-methylglutaryl coenzyme AHMG-CoA reductase\u2014the rate-limiting enzyme of cholesterol synthesis. Activation of acyl-coenzyme A:cholesterol acyltransferase (ACAT)\u2014an enzyme that increases cholesterol storage as a cholesterol ester. Reduced expression of LDL receptors on the cell surface.", "contents": "PCSK9 Inhibitors -- Mechanism of Action -- Normal Cholesterol Metabolism. LDL-C is normally cleared from the circulation as apoprotein B100 on the surface of LDL and binds to LDL receptors on hepatic and extrahepatic tissues. LDL bound to\u00a0these receptors undergoes a process of endocytosis. The endocytic vesicle fuses with lysosomes, increasing the intracellular concentration of free cholesterol. As the intracellular concentration of cholesterol increases,\u00a03 events occur, as mentioned below. [9] Decreased activity of 3-hydroxy-3-methylglutaryl coenzyme AHMG-CoA reductase\u2014the rate-limiting enzyme of cholesterol synthesis. Activation of acyl-coenzyme A:cholesterol acyltransferase (ACAT)\u2014an enzyme that increases cholesterol storage as a cholesterol ester. Reduced expression of LDL receptors on the cell surface."}
{"id": "article-37376_8", "title": "PCSK9 Inhibitors -- Mechanism of Action -- Normal Cholesterol Metabolism", "content": "In this highly integrated system, as the cell takes up more cholesterol by this normal LDL-receptor pathway, de novo production of cholesterol decreases, and less is taken up by the LDL receptors. When LDL levels are particularly\u00a0high or undergo modification, such as glycation or oxidation, they are more apt to be taken up by the scavenger pathway on endothelial cells, leading to the development of atherosclerotic plaques and vascular disease.", "contents": "PCSK9 Inhibitors -- Mechanism of Action -- Normal Cholesterol Metabolism. In this highly integrated system, as the cell takes up more cholesterol by this normal LDL-receptor pathway, de novo production of cholesterol decreases, and less is taken up by the LDL receptors. When LDL levels are particularly\u00a0high or undergo modification, such as glycation or oxidation, they are more apt to be taken up by the scavenger pathway on endothelial cells, leading to the development of atherosclerotic plaques and vascular disease."}
{"id": "article-37376_9", "title": "PCSK9 Inhibitors -- Mechanism of Action -- Normal Cholesterol Metabolism", "content": "An important concept to recognize is that LDL receptors continually recycle back to the cell surface, where they bind and clear more LDL-C. PCSK9, a product of hepatocytes, is secreted into the plasma, where it binds to the LDL receptors, facilitating their lysosomal degradation. Thus, PCSK9 reduces the expression of LDL receptors on the cell membrane,\u00a0decreasing the clearance of LDL-C.", "contents": "PCSK9 Inhibitors -- Mechanism of Action -- Normal Cholesterol Metabolism. An important concept to recognize is that LDL receptors continually recycle back to the cell surface, where they bind and clear more LDL-C. PCSK9, a product of hepatocytes, is secreted into the plasma, where it binds to the LDL receptors, facilitating their lysosomal degradation. Thus, PCSK9 reduces the expression of LDL receptors on the cell membrane,\u00a0decreasing the clearance of LDL-C."}
{"id": "article-37376_10", "title": "PCSK9 Inhibitors -- Mechanism of Action -- Normal Cholesterol Metabolism", "content": "Statins decrease HMG-CoA reductase activity, reducing cholesterol synthesis. Reduced intracellular cholesterol leads to increased recycling and the expression of LDL receptors on the cell surface. This, in turn, allows for increased clearance of LDL-C by\u00a0the non-atherogenic receptor-mediated pathway, leaving less LDL to be taken up by the scavenger pathway. Statins increase the activity of PCSK9. While statins effectively decrease cholesterol levels, their efficacy is diminished by this increase in PCSK9 activity.", "contents": "PCSK9 Inhibitors -- Mechanism of Action -- Normal Cholesterol Metabolism. Statins decrease HMG-CoA reductase activity, reducing cholesterol synthesis. Reduced intracellular cholesterol leads to increased recycling and the expression of LDL receptors on the cell surface. This, in turn, allows for increased clearance of LDL-C by\u00a0the non-atherogenic receptor-mediated pathway, leaving less LDL to be taken up by the scavenger pathway. Statins increase the activity of PCSK9. While statins effectively decrease cholesterol levels, their efficacy is diminished by this increase in PCSK9 activity."}
{"id": "article-37376_11", "title": "PCSK9 Inhibitors -- Mechanism of Action -- PCSK9", "content": "Familial hypercholesterolemia is characterized by high total and LDL-C levels, premature vascular disease, and tendon xanthomas. In most cases, this is due to a genetic mutation of the LDL receptor caused by mutations of the apoprotein B100 or PCSK9 genes. In 2003, researchers reported a family in France with the familial hypercholesterolemia phenotype without an identifiable mutation of the LDL receptor or apoprotein B100. [10] Affected family members were discovered to have a gain of function mutation of a serine protease, PCSK9. Transgenic mice overexpressing PCSK9 have reduced LDL-R function and elevated LDL, while PCSK9 knockout mice have increased LDL-R activity and low LDL-C levels. A longitudinal epidemiologic study found subjects with loss of function mutations in PCSK9 had a modest reduction in LDL-C but a more significant decrease in coronary heart disease. [11]", "contents": "PCSK9 Inhibitors -- Mechanism of Action -- PCSK9. Familial hypercholesterolemia is characterized by high total and LDL-C levels, premature vascular disease, and tendon xanthomas. In most cases, this is due to a genetic mutation of the LDL receptor caused by mutations of the apoprotein B100 or PCSK9 genes. In 2003, researchers reported a family in France with the familial hypercholesterolemia phenotype without an identifiable mutation of the LDL receptor or apoprotein B100. [10] Affected family members were discovered to have a gain of function mutation of a serine protease, PCSK9. Transgenic mice overexpressing PCSK9 have reduced LDL-R function and elevated LDL, while PCSK9 knockout mice have increased LDL-R activity and low LDL-C levels. A longitudinal epidemiologic study found subjects with loss of function mutations in PCSK9 had a modest reduction in LDL-C but a more significant decrease in coronary heart disease. [11]"}
{"id": "article-37376_12", "title": "PCSK9 Inhibitors -- Mechanism of Action -- PCSK9", "content": "Understanding these basic principles of cholesterol metabolism led to the hypothesis that measures to reduce PCSK9 activity would lower LDL-C levels and possibly reduce the risk of cardiovascular disease.\u00a0Three\u00a0pharmaceutical products in the United States reduce PCSK9 activity: alirocumab, evolocumab, and inclisiran.\u00a0Alirocumab and evolocumab are fully humanized monoclonal antibodies injected subcutaneously at intervals every 2 to 4 weeks, effectively lowering total and LDL-C. Whether used as monotherapy or combined with a statin, they typically reduce LDL-C levels by 50% to 60%. The effect is sustained as long as treatment continues. [12] [13] [14] Inclisiran is a small interfering mRNA that inhibits the intracellular synthesis of PCSK9. When administered to patients on maximally tolerated statin therapy, inclisiran reduces LDL-C by 50%. [4] [5]", "contents": "PCSK9 Inhibitors -- Mechanism of Action -- PCSK9. Understanding these basic principles of cholesterol metabolism led to the hypothesis that measures to reduce PCSK9 activity would lower LDL-C levels and possibly reduce the risk of cardiovascular disease.\u00a0Three\u00a0pharmaceutical products in the United States reduce PCSK9 activity: alirocumab, evolocumab, and inclisiran.\u00a0Alirocumab and evolocumab are fully humanized monoclonal antibodies injected subcutaneously at intervals every 2 to 4 weeks, effectively lowering total and LDL-C. Whether used as monotherapy or combined with a statin, they typically reduce LDL-C levels by 50% to 60%. The effect is sustained as long as treatment continues. [12] [13] [14] Inclisiran is a small interfering mRNA that inhibits the intracellular synthesis of PCSK9. When administered to patients on maximally tolerated statin therapy, inclisiran reduces LDL-C by 50%. [4] [5]"}
{"id": "article-37376_13", "title": "PCSK9 Inhibitors -- Administration -- Available Dosage Forms, Strengths, and Dosages", "content": "Alirocumab: Alirocumab offers flexible dosing options, as mentioned below. Alirocumab is supplied in a 75- or 150-mg single-dose prefilled pen. The recommended starting dosage is 75 mg every\u00a02 weeks, administered subcutaneously. An alternative starting dosage regimen is 300 mg every\u00a04 weeks. If the LDL-C response is inadequate, the dosage may be adjusted to the maximum dosage of 150 mg administered every\u00a02 weeks. No pediatric dosing is recommended for this drug. Evolocumab: Evolocumab\u00a0offers flexible dosing options, as mentioned below. Evolocumab is supplied as a 140 mg/mL single-use prefilled syringe or autoinjector and a 420 mg/3.5 mL solution in a single-use infusor with a prefilled cartridge. For adults, the dosing is 140 mg every\u00a02 weeks or 420 mg monthly, administered subcutaneously. The 420 mg dose can be administered over 5 minutes using the single-use infusor or by consecutively giving 3 140 mg injections within 30 minutes.", "contents": "PCSK9 Inhibitors -- Administration -- Available Dosage Forms, Strengths, and Dosages. Alirocumab: Alirocumab offers flexible dosing options, as mentioned below. Alirocumab is supplied in a 75- or 150-mg single-dose prefilled pen. The recommended starting dosage is 75 mg every\u00a02 weeks, administered subcutaneously. An alternative starting dosage regimen is 300 mg every\u00a04 weeks. If the LDL-C response is inadequate, the dosage may be adjusted to the maximum dosage of 150 mg administered every\u00a02 weeks. No pediatric dosing is recommended for this drug. Evolocumab: Evolocumab\u00a0offers flexible dosing options, as mentioned below. Evolocumab is supplied as a 140 mg/mL single-use prefilled syringe or autoinjector and a 420 mg/3.5 mL solution in a single-use infusor with a prefilled cartridge. For adults, the dosing is 140 mg every\u00a02 weeks or 420 mg monthly, administered subcutaneously. The 420 mg dose can be administered over 5 minutes using the single-use infusor or by consecutively giving 3 140 mg injections within 30 minutes."}
{"id": "article-37376_14", "title": "PCSK9 Inhibitors -- Administration -- Available Dosage Forms, Strengths, and Dosages", "content": "For children aged 10 and older with heterozygous familial hypercholesterolemia, dosing is 140 mg subcutaneously every\u00a02 weeks or 420 mg subcutaneously monthly. For adults and children aged 10 and older with homozygous familial hypercholesterolemia, the dosage is 420 mg subcutaneously\u00a0monthly but can be increased to 420 mg every 2 weeks if a clinically meaningful response is not achieved in 12 weeks. Inclisiran: The recommended dosage option for inclisiran is mentioned below. Inclisiran is supplied in a 284 mg/1.5 mL prefilled syringe. The recommended dosage of inclisiran\u00a0consists of a 284-mg subcutaneous injection initially, followed by a second dose at 3 months, and subsequent doses every 6 months thereafter.", "contents": "PCSK9 Inhibitors -- Administration -- Available Dosage Forms, Strengths, and Dosages. For children aged 10 and older with heterozygous familial hypercholesterolemia, dosing is 140 mg subcutaneously every\u00a02 weeks or 420 mg subcutaneously monthly. For adults and children aged 10 and older with homozygous familial hypercholesterolemia, the dosage is 420 mg subcutaneously\u00a0monthly but can be increased to 420 mg every 2 weeks if a clinically meaningful response is not achieved in 12 weeks. Inclisiran: The recommended dosage option for inclisiran is mentioned below. Inclisiran is supplied in a 284 mg/1.5 mL prefilled syringe. The recommended dosage of inclisiran\u00a0consists of a 284-mg subcutaneous injection initially, followed by a second dose at 3 months, and subsequent doses every 6 months thereafter."}
{"id": "article-37376_15", "title": "PCSK9 Inhibitors -- Administration -- Available Dosage Forms, Strengths, and Dosages", "content": "No dosage adjustment is necessary for patients with mild or moderately impaired hepatic or renal function. However, currently, no available data exist on the use of alirocumab, evolocumab, and inclisiran in patients with severe hepatic dysfunction. Specifically for alirocumab, there is a lack of data regarding patients with severe renal impairment, and for inclisiran, data are unavailable for those with end-stage renal disease.", "contents": "PCSK9 Inhibitors -- Administration -- Available Dosage Forms, Strengths, and Dosages. No dosage adjustment is necessary for patients with mild or moderately impaired hepatic or renal function. However, currently, no available data exist on the use of alirocumab, evolocumab, and inclisiran in patients with severe hepatic dysfunction. Specifically for alirocumab, there is a lack of data regarding patients with severe renal impairment, and for inclisiran, data are unavailable for those with end-stage renal disease."}
{"id": "article-37376_16", "title": "PCSK9 Inhibitors -- Administration -- Efficacy of the Drugs", "content": "Decreases LDL-C by 45% to 65%. Decreases apoprotein B by 40% to 50%. Decreases lipoprotein\u00a0(a) by 30% to 40%. Decreases triglyceride by 8% to 10%. Increases HDL cholesterol by 8% to 10%. Increases apoprotein A1 by 4% to 5%. [12] [15]", "contents": "PCSK9 Inhibitors -- Administration -- Efficacy of the Drugs. Decreases LDL-C by 45% to 65%. Decreases apoprotein B by 40% to 50%. Decreases lipoprotein\u00a0(a) by 30% to 40%. Decreases triglyceride by 8% to 10%. Increases HDL cholesterol by 8% to 10%. Increases apoprotein A1 by 4% to 5%. [12] [15]"}
{"id": "article-37376_17", "title": "PCSK9 Inhibitors -- Administration -- Outcomes data", "content": "Short- and long-term studies have shown a significant reduction in cardiovascular events with alirocumab and evolocumab. [2] [15] [16] Cardiovascular outcomes trials for inclisiran are being conducted, but no published results exist. [5] Intravascular ultrasound evidence of plaque regression in patients on PCSK9 inhibitors (GLAGOV study). [17] Decreased plaque volume and plaque regression in a more significant percentage of treated subjects than with placebo. Evolocumab versus placebo\u00a0for 76 weeks.", "contents": "PCSK9 Inhibitors -- Administration -- Outcomes data. Short- and long-term studies have shown a significant reduction in cardiovascular events with alirocumab and evolocumab. [2] [15] [16] Cardiovascular outcomes trials for inclisiran are being conducted, but no published results exist. [5] Intravascular ultrasound evidence of plaque regression in patients on PCSK9 inhibitors (GLAGOV study). [17] Decreased plaque volume and plaque regression in a more significant percentage of treated subjects than with placebo. Evolocumab versus placebo\u00a0for 76 weeks."}
{"id": "article-37376_18", "title": "PCSK9 Inhibitors -- Administration -- Outcomes data", "content": "FOURIER (evolocumab): Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk. [18] Studied 27,564 subjects aged 40 and older\u00a0or\u00a085 and younger with clinically evident cardiovascular disease at high risk for a recurrent event with LDL-C\u00a0greater than or equal to 70 mg/dL or non-HDL-C\u00a0greater than or equal to\u00a0100 mg/dL and triglycerides\u00a0less than or equal to\u00a0400 mg/dL. 15% reduction in the primary end point, composite of cardiovascular death, MI, stroke, hospitalization for unstable angina, or coronary revascularization, hazard ratio, 0.85; 95% CI, 0.79 to 0.92. 20%\u00a0reduction in the secondary end point of cardiovascular death, MI, or stroke, hazard ratio, 0.80; 95% CI, 0.73 to 0.88.", "contents": "PCSK9 Inhibitors -- Administration -- Outcomes data. FOURIER (evolocumab): Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk. [18] Studied 27,564 subjects aged 40 and older\u00a0or\u00a085 and younger with clinically evident cardiovascular disease at high risk for a recurrent event with LDL-C\u00a0greater than or equal to 70 mg/dL or non-HDL-C\u00a0greater than or equal to\u00a0100 mg/dL and triglycerides\u00a0less than or equal to\u00a0400 mg/dL. 15% reduction in the primary end point, composite of cardiovascular death, MI, stroke, hospitalization for unstable angina, or coronary revascularization, hazard ratio, 0.85; 95% CI, 0.79 to 0.92. 20%\u00a0reduction in the secondary end point of cardiovascular death, MI, or stroke, hazard ratio, 0.80; 95% CI, 0.73 to 0.88."}
{"id": "article-37376_19", "title": "PCSK9 Inhibitors -- Administration -- Outcomes data", "content": "ODYSSEY (alirocumab): Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab. [19] Studied 18,924 subjects aged 40 or older, hospitalized with an acute coronary syndrome 1 to 12 months before randomization, and had an LDL-C of at least 70 mg/dL, a non-HDL-C of at least 100 mg/dL, or an apolipoprotein B level of at least 80 mg/dL. 15%\u00a0reduction in the primary end point, a composite of death from coronary heart disease, nonfatal MI, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization, hazard ratio, 0.85; 95% CI, 0.78 to 0.93 15%\u00a0reduction in the secondary end point, and coronary heart disease event, major coronary heart disease events, any cardiovascular event, and a composite of death from any cause, nonfatal MI, or nonfatal ischemic stroke, hazard ratio, 0.85; 95% CI, 0.73 to 0.98. The absolute benefit was more significant among patients with a baseline LDL level greater than or equal to 100 mg/dL.", "contents": "PCSK9 Inhibitors -- Administration -- Outcomes data. ODYSSEY (alirocumab): Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab. [19] Studied 18,924 subjects aged 40 or older, hospitalized with an acute coronary syndrome 1 to 12 months before randomization, and had an LDL-C of at least 70 mg/dL, a non-HDL-C of at least 100 mg/dL, or an apolipoprotein B level of at least 80 mg/dL. 15%\u00a0reduction in the primary end point, a composite of death from coronary heart disease, nonfatal MI, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization, hazard ratio, 0.85; 95% CI, 0.78 to 0.93 15%\u00a0reduction in the secondary end point, and coronary heart disease event, major coronary heart disease events, any cardiovascular event, and a composite of death from any cause, nonfatal MI, or nonfatal ischemic stroke, hazard ratio, 0.85; 95% CI, 0.73 to 0.98. The absolute benefit was more significant among patients with a baseline LDL level greater than or equal to 100 mg/dL."}
{"id": "article-37376_20", "title": "PCSK9 Inhibitors -- Administration -- Cost of the Drugs", "content": "The drugs are expensive. In the United States, alirocumab and evolocumab are priced at $5,800 to $6,500 annually, whereas inclisiran costs $9,750 for the first year and $6500 annually thereafter. [2] The drugs require prior authorization. Generally recommended for patients with established or at high risk for cardiovascular disease who cannot achieve adequate lowering of LDL-C with maximally tolerated statin \u00b1 ezetimibe or who are statin-intolerant. The American College of Cardiology and the National Lipid Association 2022 published guidelines on the use of PCSK9 inhibitors and other nonstatin therapies: PCSK9 inhibitors are recommended for several patient populations. [15] These include the following: In patients with cardiovascular disease at very high risk whose LDL-C level remains \u226555 mg/dL (\u22651.42 mmol/L) on a maximally tolerated statin, adding a PCSK9 inhibitor is reasonable.", "contents": "PCSK9 Inhibitors -- Administration -- Cost of the Drugs. The drugs are expensive. In the United States, alirocumab and evolocumab are priced at $5,800 to $6,500 annually, whereas inclisiran costs $9,750 for the first year and $6500 annually thereafter. [2] The drugs require prior authorization. Generally recommended for patients with established or at high risk for cardiovascular disease who cannot achieve adequate lowering of LDL-C with maximally tolerated statin \u00b1 ezetimibe or who are statin-intolerant. The American College of Cardiology and the National Lipid Association 2022 published guidelines on the use of PCSK9 inhibitors and other nonstatin therapies: PCSK9 inhibitors are recommended for several patient populations. [15] These include the following: In patients with cardiovascular disease at very high risk whose LDL-C level remains \u226555 mg/dL (\u22651.42 mmol/L) on a maximally tolerated statin, adding a PCSK9 inhibitor is reasonable."}
{"id": "article-37376_21", "title": "PCSK9 Inhibitors -- Administration", "content": "In patients with cardiovascular disease not at very high risk whose LDL-C remains \u226570 mg/dL (\u22651.81 mmol/L) on a maximally tolerated statin, adding a PCSK9 inhibitor is reasonable. In patients with severe primary hypercholesterolemia (LDL-C level \u2265190 mg/dL [\u22654.91 mmol/L]), without familial hypercholesterolemia, if the LDL-C level on statin \u226570 mg/dL (\u22651.81 mmol/L) a PCSK9 inhibitor may be considered. In patients with severe primary hypercholesterolemia (LDL-C level \u2265190 mg/dL [\u22654.91 mmol/L]), with a diagnosis of familial hypercholesterolemia, if the LDL-C level on statin \u226555 mg/dL (\u22651.42 mmol/L) a PCSK9 inhibitor may be considered. In patients without clinical cardiovascular disease and with baseline LDL-C \u2265190 mg/dL\u00a0on a statin for primary prevention, if the LDL-C level on statin \u2265100 mg/dL (\u22652.59 mmol/L), a PCSK9 inhibitor may be considered.", "contents": "PCSK9 Inhibitors -- Administration. In patients with cardiovascular disease not at very high risk whose LDL-C remains \u226570 mg/dL (\u22651.81 mmol/L) on a maximally tolerated statin, adding a PCSK9 inhibitor is reasonable. In patients with severe primary hypercholesterolemia (LDL-C level \u2265190 mg/dL [\u22654.91 mmol/L]), without familial hypercholesterolemia, if the LDL-C level on statin \u226570 mg/dL (\u22651.81 mmol/L) a PCSK9 inhibitor may be considered. In patients with severe primary hypercholesterolemia (LDL-C level \u2265190 mg/dL [\u22654.91 mmol/L]), with a diagnosis of familial hypercholesterolemia, if the LDL-C level on statin \u226555 mg/dL (\u22651.42 mmol/L) a PCSK9 inhibitor may be considered. In patients without clinical cardiovascular disease and with baseline LDL-C \u2265190 mg/dL\u00a0on a statin for primary prevention, if the LDL-C level on statin \u2265100 mg/dL (\u22652.59 mmol/L), a PCSK9 inhibitor may be considered."}
{"id": "article-37376_22", "title": "PCSK9 Inhibitors -- Administration", "content": "For patients with statin-associated adverse effects, a PCSK9 inhibitor may be considered for those with clinical cardiovascular disease or baseline LDL-C \u2265190 mg/dL (\u22654.91 mmol/L). Inclisiran may be considered in patients who have demonstrated poor adherence to PCSK9 monoclonal antibodies, have adverse effects from both PSCK9 monoclonal antibodies, or cannot adhere to\u00a0a\u00a0self-injection regimen. The specific details of these guidelines formulated by the ACC and NLA are cited in the references at the end of this article.", "contents": "PCSK9 Inhibitors -- Administration. For patients with statin-associated adverse effects, a PCSK9 inhibitor may be considered for those with clinical cardiovascular disease or baseline LDL-C \u2265190 mg/dL (\u22654.91 mmol/L). Inclisiran may be considered in patients who have demonstrated poor adherence to PCSK9 monoclonal antibodies, have adverse effects from both PSCK9 monoclonal antibodies, or cannot adhere to\u00a0a\u00a0self-injection regimen. The specific details of these guidelines formulated by the ACC and NLA are cited in the references at the end of this article."}
{"id": "article-37376_23", "title": "PCSK9 Inhibitors -- Adverse Effects -- Drug-Drug Interactions", "content": "Adverse effects for each of these agents are mentioned below. [15] [20]", "contents": "PCSK9 Inhibitors -- Adverse Effects -- Drug-Drug Interactions. Adverse effects for each of these agents are mentioned below. [15] [20]"}
{"id": "article-37376_24", "title": "PCSK9 Inhibitors -- Adverse Effects -- Drug-Drug Interactions", "content": "Evolocumab: Evolocumab may lead to severe reactions such as hypersensitivity reactions and angioedema, while common adverse effects encompass injection site reactions, nasopharyngitis, headache, upper respiratory tract infection, musculoskeletal pain, back pain, elevated blood pressure, diarrhea, and myalgia.", "contents": "PCSK9 Inhibitors -- Adverse Effects -- Drug-Drug Interactions. Evolocumab: Evolocumab may lead to severe reactions such as hypersensitivity reactions and angioedema, while common adverse effects encompass injection site reactions, nasopharyngitis, headache, upper respiratory tract infection, musculoskeletal pain, back pain, elevated blood pressure, diarrhea, and myalgia."}
{"id": "article-37376_25", "title": "PCSK9 Inhibitors -- Adverse Effects -- Drug-Drug Interactions", "content": "Alirocumab: Alirocumab may induce severe reactions such as hypersensitivity reactions, hypersensitivity vasculitis, and angioedema, while common adverse effects include generally mild injection-site reactions, nasopharyngitis, diarrhea, bronchitis, myalgia, muscle spasms, elevated alanine transaminase (ALT) or aspartate transaminase (AST) levels, confusion, and musculoskeletal pain.", "contents": "PCSK9 Inhibitors -- Adverse Effects -- Drug-Drug Interactions. Alirocumab: Alirocumab may induce severe reactions such as hypersensitivity reactions, hypersensitivity vasculitis, and angioedema, while common adverse effects include generally mild injection-site reactions, nasopharyngitis, diarrhea, bronchitis, myalgia, muscle spasms, elevated alanine transaminase (ALT) or aspartate transaminase (AST) levels, confusion, and musculoskeletal pain."}
{"id": "article-37376_26", "title": "PCSK9 Inhibitors -- Adverse Effects -- Drug-Drug Interactions", "content": "Inclisiran: No severe adverse events have yet been reported for inclisiran. Common reactions encompass injection site reactions, arthralgia, urinary tract infections, diarrhea, bronchitis, extremity pain, and dyspnea.", "contents": "PCSK9 Inhibitors -- Adverse Effects -- Drug-Drug Interactions. Inclisiran: No severe adverse events have yet been reported for inclisiran. Common reactions encompass injection site reactions, arthralgia, urinary tract infections, diarrhea, bronchitis, extremity pain, and dyspnea."}
{"id": "article-37376_27", "title": "PCSK9 Inhibitors -- Contraindications", "content": "Alirocumab\u00a0and\u00a0evolocumab\u00a0are contraindicated in patients with a history of hypersensitivity reactions to either of the agents. Caution is advised in giving evolocumab to patients with latex hypersensitivity. No contraindications are listed for inclisiran. [15] None of these agents currently have any significant drug-drug interactions listed. [21]", "contents": "PCSK9 Inhibitors -- Contraindications. Alirocumab\u00a0and\u00a0evolocumab\u00a0are contraindicated in patients with a history of hypersensitivity reactions to either of the agents. Caution is advised in giving evolocumab to patients with latex hypersensitivity. No contraindications are listed for inclisiran. [15] None of these agents currently have any significant drug-drug interactions listed. [21]"}
{"id": "article-37376_28", "title": "PCSK9 Inhibitors -- Monitoring", "content": "The prescriber should recheck the LDL-C after starting alirocumab, evolocumab, or inclisiran treatment. Inclisiran is dosed at\u00a0284 mg every 6 months. Evolocumab\u00a0dosing is 140 mg every\u00a02 weeks or 420 mg monthly alirocumab\u00a0usually\u00a0is started at a dose of 75 mg every\u00a02 weeks. After 4 to 8 weeks, repeat an LDL-C level.\u00a0If the LDL-C response is not adequate, increase the dose to a maximum dosage of 150 mg every\u00a02 weeks. Following the dose adjustment, remeasure the LDL-C level after 4 to 8 weeks. [1]", "contents": "PCSK9 Inhibitors -- Monitoring. The prescriber should recheck the LDL-C after starting alirocumab, evolocumab, or inclisiran treatment. Inclisiran is dosed at\u00a0284 mg every 6 months. Evolocumab\u00a0dosing is 140 mg every\u00a02 weeks or 420 mg monthly alirocumab\u00a0usually\u00a0is started at a dose of 75 mg every\u00a02 weeks. After 4 to 8 weeks, repeat an LDL-C level.\u00a0If the LDL-C response is not adequate, increase the dose to a maximum dosage of 150 mg every\u00a02 weeks. Following the dose adjustment, remeasure the LDL-C level after 4 to 8 weeks. [1]"}
{"id": "article-37376_29", "title": "PCSK9 Inhibitors -- Enhancing Healthcare Team Outcomes", "content": "Due to the cost implications associated with PCSK9 inhibitors and inclisiran, collaborative efforts among clinicians, clinical pharmacists, and specialty pharmacies are paramount to ensure patient adherence to therapy. This collaboration may entail various tasks, such as completing financial assistance paperwork, submitting prior authorizations, or acquiring manufacturer discount cards to facilitate patient access to treatment. A specialized team consisting of nurses, pharmacists, and prescribers must work collectively to ensure the safe administration of these drugs, monitor laboratory values and adverse effects, and provide comprehensive education to patients and their families. Pharmacists, including those specialized in cardiology, can provide valuable insights to prescribers regarding dosing and administration intervals. By leveraging this interprofessional approach, these novel agents can effectively achieve their therapeutic objectives, particularly in patients who have not responded adequately to statin therapy. [22] [23]", "contents": "PCSK9 Inhibitors -- Enhancing Healthcare Team Outcomes. Due to the cost implications associated with PCSK9 inhibitors and inclisiran, collaborative efforts among clinicians, clinical pharmacists, and specialty pharmacies are paramount to ensure patient adherence to therapy. This collaboration may entail various tasks, such as completing financial assistance paperwork, submitting prior authorizations, or acquiring manufacturer discount cards to facilitate patient access to treatment. A specialized team consisting of nurses, pharmacists, and prescribers must work collectively to ensure the safe administration of these drugs, monitor laboratory values and adverse effects, and provide comprehensive education to patients and their families. Pharmacists, including those specialized in cardiology, can provide valuable insights to prescribers regarding dosing and administration intervals. By leveraging this interprofessional approach, these novel agents can effectively achieve their therapeutic objectives, particularly in patients who have not responded adequately to statin therapy. [22] [23]"}
{"id": "article-37376_30", "title": "PCSK9 Inhibitors -- Review Questions", "content": "Access free multiple choice questions on this topic. Comment on this article.", "contents": "PCSK9 Inhibitors -- Review Questions. Access free multiple choice questions on this topic. Comment on this article."}